Updates are available Correction dated 2025-08-20
Click to view Correction: https://doi.org/10.1186/s13287-025-04564-3
-
Authors
Takahashi, Gou https://orcid.org/0000-0003-2277-7657
Maeda, Minato
Shinozaki, Kayoko
Harada, Gakuro
Ito, Saburo
Miyaoka, Yuichiro https://orcid.org/0000-0002-8874-4738
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K21409, 20H03442, 24K02028, 18K15054, 22K15386)
Japan Agency for Medical Research and Development (23jm0610092h0001)
Takeda Science Foundation (Takeda Science Foundation)
Sumitomo Foundation (Sumitomo Foundation)
Ichiro Kanehara Foundation (Ichiro Kanehara Foundation)
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 22 May 2025
First Online: 7 June 2025
Change Date: 20 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13287-025-04564-3
Declarations
:
: This study is a part of the research entitled “Development of disease models and cell transplantation therapies by precise genome editing in human iPS cells”, which was approved by the Ethics Committee on Human Subjects Research of the Tokyo Metropolitan Institute of Medical Science (TMIMS) on March 9, 2022, and was conducted in accordance with these guidelines (Approval number; 21–49). This study did not involve any human participants or identifiable personal data. The generation process of the WTC11 iPS line was approved by the University of California San Francisco Committee on human research (Approval number; 10-02521), and the donor has signed an informed consent form [ ].
: All authors agreed to publication.
: G.H. and S.I. are employees of Yamaha Motor Co. Ltd. All other authors declare no conflicts of interest in association with the present study.
